Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

December 10, 2007

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Methotrexate

Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg daily.

DRUG

Abatacept

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Adalimumab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Azathioprine

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Baricitinib

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Certolizumab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Etanercept

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Golimumab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Hydroxychloroquine

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Infliximab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Leflunomide

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Minocycline

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Rituximab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Sarilumab

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Sulfasalazine

Starting dose may be adjusted as needed at investigator's discretion.

DRUG

Tofacitinib

Starting dose may be adjusted as needed at investigator's discretion.

Trial Locations (1)

68198

RECRUITING

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER